Compare MasTec Inc (MTZ) vs Revvity Inc (RVTY) Price & Performance

MasTec (MTZ) trades at $212.65, down 4.8% amid bearish technical signals, though recent earnings show mixed results with two beats and one miss. The company maintains strong analyst support with 88.9% buy ratings and a $408.58 consensus target, supported by record $21.4B backlog and infrastructure demand growth. Revenue reached $14.3B in 2025 with 3.07% net margin, while valuation ratios appear elevated with P/E of 34.5.

MTZ presents a compelling infrastructure growth story with AI and data center exposure, though premium valuation and weak cash flow pose near-term risks. The stock's current discount to analyst targets offers potential upside if execution improves, but investors should monitor communications segment softness and margin pressures in a competitive contracting environment.

Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.

The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.